Gilead Sciences, Inc.
NEWS
The company is pledging to support a goal to end HIV in the U.S. by 2030 announced by the president during the State of the Union this year.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
Under the terms of the deal, Gilead holds exclusive options to license worldwide rights to specific products directed toward targets coming out of Goldfinch’s proprietary Kidney Genome Atlas.
Despite continued slumps in sales of its hepatitis C medications, Gilead Sciences saw a robust first quarter, with earnings up nearly 28 percent. That was good news as new Chief Executive Officer Dan O’Day marked his first full quarter with the California-based company.
For those select few who achieve the role of chief executive officer of a multi-national corporation, the compensation packages are typically quite large – especially when compared to the average salaries of company employees.
Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.
NHS England will acquire hepatitis C drugs from the companies at competitive prices and work to identify patients around the country.
On Wednesday, Kite and Gilead announced the 20-acre facility in Fredericksburg that is expected to employ more than 400 people when it becomes operational.
The U.S. Department of Justice (DOJ) is reviewing a government patent for HIV, according to a retired Centers for Disease Control and Prevention (CDC) scientist.
JOBS
IN THE PRESS